James Lovgren is the CEO and Co-founder of Aspiro Therapeutics, a preclinical-stage company developing a novel inhaled peptide therapeutic for obstructive lung diseases. The company’s lead program focuses on a CC16-derived peptidomimetic designed to address underlying disease biology in asthma […]